Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.
Price history
Loading AARD daily closes…
Loading price history…
Pipeline assets
ARD-101
Phase 3 · ActiveModality: small molecule
Target TAS2Rs (bitter taste receptors)
Indications
Hyperphagia associated with Prader-Willi syndrome (PWS)(Phase 3)
Status note FDA clinical hold on the ARD-101 program (May 2026) following reversible cardiac observations in a healthy volunteer study (QRS duration increases at supratherapeutic dose); the Phase 3 HERO trial and the OLE trial were terminated in June 2026. The company is evaluating whether and how to pursue further development, including a potentially redesigned trial; previously guided HERO topline in Q3 2026 is withdrawn, so no dated catalyst is stated.
Obesity and obesity-related conditions, including prevention of weight regain following GLP-1RA therapy(Phase 2)
Status note Fixed-dose combination of ARD-101 and a DPP-4 inhibitor (STRENGTH acronym states sitagliptin). POWER (Phase 2, initiated Dec 2025) and planned STRENGTH trials were paused in Feb 2026; further development depends on resolution of the ARD-101 clinical hold. Not explicitly discontinued.
Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.